Duchenne Muscular Dystrophy (DMD) Clinical Trial
Official title:
A Single-arm, Open-label, Single-center Study to Evaluate the Safety and Tolerability of Intravenous GEN6050X Gene Therapy in Ambulatory Boys With Duchenne Muscular Dystrophy (DMD).
The study will evaluate the safety and tolerability of GEN6050X gene therapy in Duchenne muscular dystrophy (DMD) patients amenable to exon 50 skipping.
GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug containing dual single-stranded adeno-associated virus serotype 9 (ss.AAV9) vectors. The study is a first-in-human, single-arm, open-label, single-center clinical trial to evaluate safety and tolerability of a single intravenous infusion of GEN6050X in ambulatory boys with DMD. Other objectives include pharmacokinetics, pharmacodynamics, and the preliminary clinical efficacy of GEN6050X over 52 weeks. A total of three ambulatory pediatric participants (aged 4 to 9 years old) are expected to enroll, each receiving a dose of 5×10^13 vg/kg. These participants will be dosed in a staggered fashion. Safety assessments will include monitoring of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations throughout the study duration. In addition, a comprehensive short-term prophylactic immunosuppression regimen(including rituximab and sirolimus) will be administered prior to treatment in order to mitigate potential immune response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02814019 -
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
|
Phase 3 | |
| Completed |
NCT01478022 -
To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20
|
Phase 1 | |
| Completed |
NCT00654784 -
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Recruiting |
NCT02614820 -
The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD
|
N/A | |
| Withdrawn |
NCT02036463 -
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT02255552 -
Study of Eteplirsen in DMD Patients
|
Phase 3 | |
| Completed |
NCT01982695 -
Cardiomyopathy in DMD: Lisinopril vs. Losartan
|
N/A | |
| Recruiting |
NCT05516745 -
E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
|
N/A | |
| Completed |
NCT02420379 -
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
| Active, not recruiting |
NCT05135663 -
Extension Study of NS-089/NCNP-02 in DMD
|
Phase 2 | |
| Completed |
NCT01380964 -
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
|
N/A | |
| Completed |
NCT05990608 -
Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT04322357 -
Twice Weekly Steroids and Exercise as Therapy for DMD
|
Phase 2 | |
| Completed |
NCT01540409 -
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Terminated |
NCT04184882 -
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
| Terminated |
NCT04254172 -
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT05524883 -
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
|
Phase 1/Phase 2 | |
| Completed |
NCT01761292 -
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
|
Phase 1/Phase 2 |